Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
17 Risultato/i
Sperimentazione in fase di reclutamento
= ; Sperimentazione in corso
=
; Finanziato da un ente associato a IRDiRC =
; Membro di una ERN =
Sperimentazioni cliniche nazionali

AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
LEROS: External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON) (Phase 4) - AT
Institution: Information not provided - AT

FRANCIA
ILE-DE-FRANCE
PARIS
RESCUE: A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene (Phase III) - FR
Centre hospitalier national d'ophtalmologie des Quinze-Vingts
Centre de Référence REFERET

FRANCIA
ILE-DE-FRANCE
PARIS
REVERSE: Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene (Phase III) - FR
Centre hospitalier national d'ophtalmologie des Quinze-Vingts
Centre de Référence REFERET

FRANCIA
ILE-DE-FRANCE
PARIS

An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Tolerability of GS010 (rAAV2/2-ND4) in Patients With Leber Hereditary Optic Neuropathy Due to Mutations in the Mitochondrial NADH Dehydrogenase 4 Gene (Phase I-II)
Institut de la Vision
Centre d'Investigation Clinique (CIC) de l'hôpital des Quinze-Vingts

GERMANIA
Bayern
MÜNCHEN
RESCUE: A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene (Phase III) -DE-
Friedrich-Baur-Institut
Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik

GERMANIA
Bayern
MÜNCHEN
RESCUE/REVERSE: Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials -DE-
Friedrich-Baur-Institut
Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik

GERMANIA
Bayern
MÜNCHEN
The KHENERGYZE Study: A Phase IIb Double-blind, Randomised, Placebo-controlled, Multi-centre, Confirmative Three-way Cross-over Study on Cognitive Function With Two Doses of KH176 in Subjects With a Genetically Confirmed Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation
Friedrich-Baur-Institut
Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik

REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON

RESCUE/REVERSE: Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials-GB
Moorfield's Eye Hospital

REGNO UNITO; GRAN BRETAGNA
Tyne & Wear
NEWCASTLE-UPON-TYNE

Phase II Feasibility Study of the Efficacy and Acceptability of a Low Residue Diet in Adult Patients With Mitochondrial Disease
Faculty of Medical Sciences Newcastle University
Institute for Ageing and Health

REGNO UNITO; GRAN BRETAGNA
West Yorkshire
LEEDS

SPAGNA
Madrid
MADRID
LEROS: External Natural History Controlled, open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment with Raxone® in Leber's Hereditary Optic Neuropathy (LHON) (Phase IV) - ES
Hospital Universitario Ramón y Cajal
Servicio de Oftalmología

SPAGNA
Madrid
MADRID
REFLECT: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected with G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year (Phase III) - ES
Hospital Universitario Ramón y Cajal
Servicio de Oftalmología

STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene -GB
Institution: Information not provided - US
Sperimentazioni cliniche internazionali

GERMANIA
Baden-Württemberg
LÖRRACH
A double-blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of patients with Leber's Hereditary Optic Neuropathy (LHON) (Phase II) (coordination)
Santhera Pharmaceuticals (Deutschland) GmbH

PAESI BASSI
Gelderland
NIJMEGEN

STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene
Institution: Information not provided - US

SVIZZERA
Suisse Alémanique
LIESTAL